Intravenous Immunoglobulin (IVIG) is a therapy treatment for patients with antibody deficiencies. It is prepared from a pool of immunoglobulins (antibodies) from the plasma of thousands of healthy donors. Immunoglobulins are made by the immune system of healthy people for the purpose of fighting infections. The intravenous immunoglobulin in United States market is expected to increase by USD 2.5 十億, 年複合成長率で (CAGR) の 6.4% から 2022 に 2028, according to the latest edition of the Intravenous Immunoglobulin Market in United States Report.

このレポートは、現在の世界市場シナリオに関する詳細な分析と洞察を提供します。, latest trends and drivers into intravenous immunoglobulin market in United States. 市場規模などのさまざまな詳細について独自の洞察を提供します, 主要なトレンド, 競争環境, 成長率と市場セグメント. This study also provides an analysis of the impact of the COVID-19 crisis on the intravenous immunoglobulin industry.

This industry report offers market estimates and forecasts of the United States market, 続いてアプリケーションの詳細な分析, とエンドユーザー. The United States market for intravenous immunoglobulin can be segmented by application: chronic inflammatory demyelinating polyneuropathy (CIDP), chronic lymphocytic leukemia, congenital HIV/AIDS, guillain-barre syndrome (GBS), hypogammaglobulinemia, immune thrombocytopenic purpura (ITP), immunodeficiency diseases, kawasaki disease, multifocal motor neuropathy (MMN), myasthenia gravis, その他. The immunodeficiency diseases segment held the largest revenue share in 2021. Intravenous immunoglobulin market is further segmented by end user: ホームケア, 病院 & クリニック.

用途別:
– chronic inflammatory demyelinating polyneuropathy (CIDP)
– chronic lymphocytic leukemia
– congenital HIV/AIDS
– guillain-barre syndrome (GBS)
– hypogammaglobulinemia
– immune thrombocytopenic purpura (ITP)
– immunodeficiency diseases
– kawasaki disease
– multifocal motor neuropathy (MMN)
– myasthenia gravis
– その他

エンドユーザー別:
– ホームケア
– 病院 & クリニック

The market research report covers the analysis of key stake holders of the intravenous immunoglobulin market in United States. Some of the leading players profiled in the report include ADMA Biologics Inc., Biotest AG, CSL Limited, Grifols, SA, ジョンソン & ジョンソン, Kedrion Biopharma Inc. (Kedrion SpA), LFB S.A., Octapharma AG, Takeda Pharmaceutical Company Limited, とりわけ.
*無料サンプルをリクエストして企業の完全なリストを入手してください

歴史的 & 予測期間
この調査レポートは、以下の各セグメントの分析を提供します。 2018 に 2028 検討中 2021 基準年となる.

報告書の範囲
– To analyze and forecast the market size of the intravenous immunoglobulin market in United States.
– To classify and forecast the intravenous immunoglobulin market in United States based on application, エンドユーザー.
– To identify drivers and challenges for the intravenous immunoglobulin market in United States.
– 合併などの競争展開を検討するため & 買収, 協定, コラボレーションとパートナーシップ, 等, in the intravenous immunoglobulin market in United States.
– To identify and analyze the profile of leading players operating in the intravenous immunoglobulin market in United States.

このレポートを選択する理由
– Gain a reliable outlook of the intravenous immunoglobulin market in United States forecasts from 2022 に 2028 シナリオ全体にわたって.
– 投資対象となる成長セグメントを特定する.
– 会社概要と市場データを通じて競合他社に先んじる.
– Excel 形式でのシナリオ全体の分析を容易にするための市場予測.
– 3ヶ月間の戦略コンサルティングとリサーチサポート.
– シングルユーザーライセンスに提供される印刷認証.